Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Liabilities and Shareholders Equity (2016 - 2025)

International Stem Cell (ISCO) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $5.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 1.97% to $5.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $21.6 million, a 0.43% change, with the full-year FY2024 number at $5.2 million, down 4.03% from a year prior.
  • Liabilities and Shareholders Equity was $5.3 million for Q3 2025 at International Stem Cell, down from $5.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $6.0 million in Q1 2021 to a low of $4.9 million in Q3 2021.
  • A 5-year average of $5.4 million and a median of $5.4 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 17.28% in 2021, then rose 11.88% in 2023.
  • International Stem Cell's Liabilities and Shareholders Equity stood at $4.9 million in 2021, then increased by 3.82% to $5.1 million in 2022, then rose by 4.97% to $5.4 million in 2023, then dropped by 4.03% to $5.2 million in 2024, then rose by 2.11% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Liabilities and Shareholders Equity are $5.3 million (Q3 2025), $5.5 million (Q2 2025), and $5.6 million (Q1 2025).